S21-419 An integrated preclinical screening platform to identify novel empathogenic drugs and compounds Stanford scientists have developed a set of preclinical assays that are specifically designed to detect empathogenic effects of a drug that may indicate applications for that molecule in treating psychiatric diseases like PTSD. Boris Heifets Robert Malenka